GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated August 1, 2025, serves as a notification to the market regarding the company's total voting rights and capital structure. The report is filed in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R. The data reflects the company's share capital status as of July 31, 2025.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a capital structure notification.
Material Changes
The filing does not contain comparative data against prior periods or discuss material changes in financial performance. It solely reports the current state of issued share capital and treasury shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. Its sole purpose is to provide the denominator for shareholder interest calculations under FCA rules.
Key Facts for Investors
- Issued Share Capital: As of July 31, 2025, GSK Plc had 4,315,385,410 Ordinary Shares of 31.25 pence each.
- Treasury Shares: 237,044,421 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,078,340,989.
- Shareholder Notification: Shareholders should use the total voting rights figure (4,078,340,989) as the denominator to determine if they must notify their interest or changes thereto under FCA rules.
- Contact: Notifications regarding share interests should be sent to company.secretary@gsk.com.